Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina

Aim To investigate the prevalence of common genetic variants that can serve as markers of thrombophilia and warfarin pharmacogenetics in Bosnia and Herzegovina.

Methods The study was performed between August and October 2017 on 130 healthy unrelated adult volunteers from Bosnian-Herzegovinian population sample. The prevalence of the following genetic variants was determined: F5 c.1601G>A (factor V Leiden), F2 c.*97G>A (factor II or prothrombin mutation), F13A1 (factor XIII) c.103G>T, MTHFR (methyleneetetrahydrofolate reductase) c.665C>T and c.1286A>C, as well as PAI-1 (plasminogen activator inhibitor 1) c.-816A>G and c.-844G>A as markers of thrombophilia risk, and *2 and *3 alleles of CYP2C9 (cytochrome P450 2C9) and five variants of VKORC1 (vitamin K epoxide reductase complex subunit I) as markers of warfarin pharmacogenetics. DNA was isolated from buccal swabs using salting out method, while genotyping was performed using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry.

Results Minor allele frequencies for two main thrombophilia risk factors, F5 c.1601G>A and F2 c.*97G>A were 0.023 and 0.008, respectively. Combined data for the markers of warfarin pharmacogenetics imply that 57.4% study participants can be expected to metabolize warfarin at an extensive, 40.3% at intermediate, and 2.3% at a poor rate.

Conclusion This study reports the first extensive population genetic data for thrombophilia and warfarin pharmacogenetic markers in Bosnia and Herzegovina. Allele frequencies of genetic variants are within the general average for European populations, and their presence implies the necessity of introduction of personalized medicine in warfarin-mediated antithrombotic therapy.
Thrombophilia is a condition conferring the risk of venous or arterial thrombosis and can be roughly classified into hereditary and acquired. Hereditary thrombophilia encompasses loss-of-function and gain-of-function genetic variants. Derelegation of coagulation cascade caused by loss-of-function variants, as well as their penetrance level, makes them more severe than gain-of-function variants, which are, however, around 10-fold more common in the general population (1,2). Currently, seven variants in five genes are routinely genotyped as genetic risk factors of inherited thrombophilia: F5 c.1601G>A (factor V Leiden, FVL), F2 c.*97G>A (factor II G20210A or PTM, prothrombin mutation), two MTHFR (methylene-tetrahydrofolate reductase) variants, two PAI-1 (plasminogen activator inhibitor 1) variants, and F13A1 (factor XIII) c.103G>T (FXIII, V35L) (3-9). Warfarin, a coumarin derivative and vitamin K antagonist (VKA), is an oral anticoagulant taken to limit the production of coagulation factors II, VII, IX, and X. It is used for the prevention and treatment of thromboembolic events in patients with previous thromboembolism and atrial fibrillation (AF), following the implantation of artificial heart valves and vascular bypass procedures, as well as due to major orthopedic surgery (10-14).

Warfarin-mediated anticoagulation is currently considered to be a risky clinical therapy due to numerous interactions and interpatient variations in mean daily warfarin dose and narrow drug therapeutic range (10,12,13). We therefore hypothesized that a significant percentage of individuals from the general population will have minor variants in genes involved in thrombophilia risk, as well as warfarin pharmacodynamics and pharmacokinetics.

The aim of this study was to analyze the frequency of mutant alleles in two abovementioned sets of markers in Bosnia and Herzegovina (B&H). Additionally, we aimed to propose a simple and affordable method for genotyping relevant genetic variants that enables successful and safe implementation of personalized warfarin treatment in routine clinical practice.

MATERIALS AND METHODS

Sample collection and DNA isolation

Buccal swab samples were collected from 130 unrelated adult volunteers from B&H. Sample collection was performed in the medical laboratory Prolab (Sarajevo, B&H) between August and October 2017. Laboratory users were asked to participate in the study if they had no history of thrombotic events. In order to achieve a balanced distribution of participants’ demographic characteristics we included participants of both sexes, different age groups, and originating from different parts of the country as assessed by the origin of their grandparents. The size of the study population was determined according to previous population studies conducted in B&H (15,16) and was affected by financial constraints. Before agreeing to participate in the study, all participants signed the informed consent for study participation and data publication. Participants’ identity was known only to the main investigators. Ethical approval was obtained from the Ethics Committee of the International Burch University (Sarajevo, B&H) on July 6, 2017, document number 04-172-1/17. Genomic DNA was isolated from buccal swab samples using modified Miller’s protocol (17) at the International Burch University.

Genotyping procedure

All genotyping procedures were performed in Bioglobe Laboratory, Hamburg, Germany. In order to analyze thrombophilia markers and pharmacogenetic markers of warfarin metabolism, two multiplexes and one uniplex iPLEX assays were set-up as follows:

1. Multiplex reaction for seven thrombophilia markers, including F5 c.1601G>A, F2 c.*97G>A, MTHFR c.665C>T and c.1286A>C, PAI-1 c.-816A>G and c.-844G>A, and F13A1 c.103G>T;

2. Multiplex reaction for six markers of warfarin pharmacogenetics: VKORC1 (vitamin K epoxide reductase complex subunit 1) c.-1320G>A, VKORC1 c.-1639G>A, VKORC1 c.-679>A>G, VKORC1 c.174-136C>T, VKORC1 c.283+124G>C and CYP2C9 (cytochrome P450 2C9) c.1075A>C (CYP2C9*3);

3. Uniplex reaction for the marker of warfarin metabolism CYP2C9 c.430C>T (CYP2C9*2).

Primer selection and plex design was performed in Assay Design Suite v2 (Agena Bioscience, San Diego, CA, USA). PCR reactions were set-up in 384-well plate with reaction components and thermal cycling conditions as previously described (18). In order to remove leftover dNTPs, shrimp alkaline phosphatase (SAP) treatment was employed as previously described (18). A general iPLEX reaction setup and cycling protocol was employed for all plexes using single-base extension chemistry and according to Storm et al (18) using 75 cycles. Thermal
cycling was performed in GeneAmp PCR System 9700 (Applied Biosystems, Waltham, MA, USA).

Ion exchange sample conditioning was performed to remove excess cations from the sample-containing wells using Clean Resin (Agena Bioscience) (18). 15-nL samples were transferred to SpectroCHIP using MassARRAY Nanodispenser software by Agena Bioscience. Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry measurement and genotyping of the products of iPLEX reactions were performed by using two software packages (both by Agena Bioscience): SpectroACQUIRE to obtain spectra and raw data and MassARRAY Typer to design sample plates and study assays, and access and export genotype data.

Statistical analyses

**TABLE 1.** Demographic characteristics of study participants

| Characteristic | n (%) |
|----------------|-------|
| Sex            |       |
| male           | 47 (36.2) |
| female         | 83 (63.8) |
| Age group (years) |     |
| 18-25          | 54 (41.5) |
| 26-40          | 44 (33.8) |
| 41-60          | 24 (18.5) |
| >60            | 8 (6.2) |
| Region         |       |
| Bosnian Krajina and Western Bosnia | 20 (15) |
| Central Bosnia | 52 (40)  |
| Eastern Bosnia | 38 (29)  |
| Herzegovina    | 20 (15)  |

**TABLE 2.** Genotype frequencies (with absolute genotype numbers in parentheses) and allele frequencies of risk markers of thrombophilia in Bosnian-Herzegovinian population. Allele frequency values are presented as major and minor allele frequencies*

| Variant | Genotype frequency, % (n) | Allele frequency |
|---------|---------------------------|------------------|
| FVL (F5 c.1601G>A) | 95.4 (124) 4.6 (6) 0.0 (0) | G 0.977 A 0.023 |
| MTHFR C677T (c.665C>T) | 43.8 (57) 46.2 (60) 10.0 (13) | C 0.669 T 0.331 |
| PAI-1 4G/5G (c.-816A>G) | 30.0 (39) 50.8 (66) 19.2 (25) | 4G 0.554 5G 0.446 |
| FII G20210A (F2 c.*97G>A) | 98.5 (128) 1.5 (2) 0.0 (0) | G 0.992 A 0.008 |
| MTHFR c.1286A>C | 46.2 (60) 43.1 (56) 10.8 (14) | A 0.677 C 0.323 |
| PAI-1 c.-844G>A | 15.4 (20) 51.5 (67) 33.1 (43) | G 0.412 A 0.588 |
| F13A1 c.103G>T (V35L) | 50.0 (65) 36.9 (48) 13.1 (17) | G 0.685 T 0.315 |

*F2, FII – factor II, F5 – factor V, F13A1 – factor XIII variant A1, FVL – factor V Leiden, MTHFR – methylenetetrahydrofolate reductase, PAI-1 – plasminogen activator inhibitor 1.

RESULTS

The group of elderly participants was underrepresented, with 6.2% sample donors being older than 60 years, since the majority of laboratory users who rejected to participate were from this age group (Table 1). Genotype data were successfully generated for all 130 participants for thrombophilia markers and for 129 participants for pharmacogenetic markers of warfarin metabolism.

Allele frequencies for two most significant markers of inherited thrombophilia were 0.023 and 0.008 for F5 c.1601G>A and F2 c.*97G>A, respectively. Neither age nor sex were significant predictors of variant thrombophilic marker distribution (Table 2) (Fisher exact test, P values for association with age: P = 0.645 for F5 c.1601G>A, P = 0.840 for MTHFR c.665C>T, P = 0.160 for PAI-1 c.-844G>A, and P > 0.999 for the remaining variants; P values for association with sex: P = 0.190 for F5 c.1601G>A, P = 0.461 for MTHFR c.665C>T, P = 0.419 for PAI-1 c.-816A>G, P = 0.533 for F2 c.*97G>A, P = 0.366 for MTHFR c.1286A>C, P = 0.451 for PAI-1 c.-844G>A, and P > 0.999 for F13A1 c.103G>T). All study loci were in agreement with HWE (χ² test, P > 0.05 for all seven loci).
Using log likelihood ratio, two pairs of loci were found to be in strong linkage disequilibrium: 1) MTHFR c.665C>T and MTHFR c.1286A>C and 2) PAI-1 c.-816A>G and PAI-1 c.-844G>A ($P < 0.01$ in both cases).

Genotype data for markers of warfarin pharmacogenetics (Table 3) revealed that all polymorphic loci were in agreement with HWE ($P > 0.05$ for all five loci), while age and sex were not significantly associated with variant allele incidence ($P$ values for association with age: $P = 0.493$ for CYP2C9 c.430C>T and $P > 0.999$ for the remaining polymorphic loci; $P$ values for association with sex: $P = 0.294$ for CYP2C9 c.430C>T, $P = 0.342$ for CYP2C9 c.1075A>C and $P > 0.999$ for the remaining three polymorphic loci). Three analyzed polymorphic VKORC1 loci, c.-1639G>A, c.174-136C>T, and c.283 + 124G>C, were in complete linkage disequilibrium ($P < 0.001$). Statistical tests were employed only for the loci found to be polymorphic.

TABLE 3. Genotype frequencies (with absolute genotype numbers in parentheses) and allele frequencies of markers of warfarin pharmacogenetics in Bosnian-Herzegovinian population. Allele frequency values are presented as major and minor allele frequencies*

| Variant                      | Genotype distribution, % (n) | Allele frequency                  |
|------------------------------|------------------------------|-----------------------------------|
|                              | major homozygous | heterozygous | minor homozygous | major | minor |
| CYP2C9*2 (c.430C>T)          | 74.4 (96)       | 24.8 (32)   | 0.8 (1)          | C     | 0.868 |
| CYP2C9*3 (c.1075A>C)         | 82.9 (107)      | 16.3 (21)   | 0.8 (1)          | A     | 0.911 |
| VKORC1 c.-1639G>A            | 39.5 (51)       | 45.7 (59)   | 14.7 (19)        | G     | 0.624 |
| VKORC1 c.-1320G>A            | 100.0 (129)     | 0.0 (0)     | 0.0 (0)          | G     | 1.000 |
| VKORC1 c.-679A>G             | 100.0 (129)     | 0.0 (0)     | 0.0 (0)          | G     | 1.000 |
| VKORC1 c.174-136C>T          | 39.5 (51)       | 45.7 (59)   | 14.7 (19)        | C     | 0.624 |
| VKORC1 c.283 + 124G>C        | 39.5 (51)       | 45.7 (59)   | 14.7 (19)        | G     | 0.624 |

* CYP2C9 – cytochrome P450 2C9, VKORC1 – vitamin K epoxide reductase complex subunit 1.

TABLE 4. Combined VKORC1 c.-1639G>A and CYP2C9*2 and *3 genotypes in the study population from Bosnia and Herzegovina and genotype classification into extensive, intermediate, and poor metabolizer classes. The prediction of metabolizer class for each genotype was done according to Food and Drug Administration (FDA) recommendations from 2015 (23)*

| VKORC1 c.-1639G>A genotype | CYP2C9 genotype | Number of participants (n) | Percentage distribution | Metabolizer class |
|-----------------------------|-----------------|----------------------------|-------------------------|-------------------|
| GG                          | *1/*1           | 30                         | 23.3                    | extensive         |
|                             | *1/*2           | 11                         | 8.5                     | extensive         |
|                             | *1/*3           | 7                          | 5.4                     | intermediate      |
|                             | *2/*2           | 0                          | 0.0                     | N/A               |
|                             | *2/*3           | 3                          | 2.3                     | intermediate      |
|                             | *3/*3           | 0                          | 0.0                     | N/A               |
| GA                          | *1/*1           | 33                         | 25.6                    | extensive         |
|                             | *1/*2           | 15                         | 11.6                    | intermediate      |
|                             | *1/*3           | 9                          | 7.0                     | intermediate      |
|                             | *2/*2           | 1                          | 0.8                     | intermediate      |
|                             | *2/*3           | 0                          | 0.0                     | N/A               |
|                             | *3/*3           | 1                          | 0.8                     | poor              |
| AA                          | *1/*1           | 14                         | 10.9                    | intermediate      |
|                             | *1/*2           | 3                          | 2.3                     | intermediate      |
|                             | *1/*3           | 2                          | 1.6                     | poor              |
|                             | *2/*2           | 0                          | 0.0                     | N/A               |
|                             | *2/*3           | 0                          | 0.0                     | N/A               |
|                             | *3/*3           | 0                          | 0.0                     | N/A               |

* CYP2C9 – cytochrome P450 2C9, VKORC1 – vitamin K epoxide reductase complex subunit 1.
is, requiring daily warfarin dose decrease; 40.3% individuals had intermediate metabolism and 2.3% were poor warfarin metabolizers.

DISCUSSION

Thrombophilia risk markers and genetic markers of warfarin pharmacogenetics were detected in a considerable proportion of general Bosnian-Herzegovinian population. The calculated allele frequencies are close to the previously reported European average.

The minor allele frequency of FVL prevalence in our study was 0.023. A previously reported FVL prevalence rate in healthy individuals in B&H was similar (Table 5). In Central Europe (Poland, Slovakia, Czech Republic), the frequency of mutant FVL was 0.039. In East Europe (Russia, Ukraine, Belarus) it was 0.019, while in South-Eastern Europe (Croatia, Serbia/Serbia and Montenegro, Macedonia, Slovenia, Bulgaria), it was 0.025 (30). A somewhat lower FVL prevalence was reported by the 1000 Genomes Project phase III data (Table 6) (31). MAF for \( F^2 c.*97G>A \) (PTM) of 0.008 in the present research is in agreement with previous studies in B&H and worldwide (Tables 5 and 6), in which minor allele was either the least abundant or absent from the population.

\( MTHFR \) variants are globally most common in Europeans and Hispanics (Table 6), although heterozygous c.665C>T, homozygous c.1286A>C, or compound heterozygous genotypes currently seem not to have any clinical significance in thrombosis testing (9). \( MTHFR \) polymorphism is not included in the panel for inherited thrombophilia testing by the British Committee for Standards in Haematology and the British Society for Haematology. The American College of Medical Genetics and Genomics (ACMG) states that the informativeness of \( MTHFR \) testing is limited, and that homocysteine levels should be measured instead. In addition, ACMG recommends against \( MTHFR \) testing for the analysis of inherited thrombophilia, recurrent pregnancy loss, or for at-risk family members (9). c.665C>T variant has a prevalence of around 20% in Caucasians and Hispanics, 11% in Asians, and 1% in African-Americans (33). As regards \( PAI-1 \) polymorphism c.-816A>G, also known as \( PAI-1 4G/5G \), the present study reported 5G allele frequency of 0.446, which is significantly higher than previously report-

### Table 5. Summary of previous research of thrombophilic marker prevalence in Bosnia and Herzegovina*

| Study population                               | N   | MAF                          | Major findings                                      | Reference |
|-----------------------------------------------|-----|------------------------------|-----------------------------------------------------|-----------|
| Healthy B&H population                         | 130 | FVL 0.023                    | N/A                                                 | Current study |
|                                               |     | FII G20210A 0.008            |                                                     |            |
|                                               |     | \( MTHFR \) C677T 0.331      |                                                     |            |
|                                               |     | \( MTHFR \) c.1286A>C 0.323 |                                                     |            |
|                                               |     | \( PAI-1 \) 4G/5G 0.446      |                                                     |            |
|                                               |     | \( PAI-1 \) c.-844G>A 0.588 |                                                     |            |
|                                               |     | FXIIIA1 V35L 0.315           |                                                     |            |
| Healthy women                                 | 67  | FVL 0.000                    | N/A                                                 | (24)       |
| South-Eastern B&H healthy population          | 207 | FII G20210A 0.06             | N/A                                                 | (25)       |
| Healthy adults                                | 100 | FVL 0.06                     | N/A                                                 | (26)       |
| 111 DVT patients and 207 healthy controls     | 318 | FVL 0.0194 in controls and 0.105 in patients | FVL variant was significantly more common in DVT patients than in controls | (27)       |
|                                               |     | FII G20210A 0.000 in controls and 0.0136 in patients |                                                      |            |
|                                               |     | \( MTHFR \) C677T 0.2974 in controls and 0.3384 in patients |                                                      |            |
| 154 women who experienced PL and 154 female controls | 308 | FVL 0.039 in both controls and patients | none of three investigated markers was significantly correlated with the risk of PL | (28)       |
|                                               |     | FII G20210A 0.016 in controls and 0.019 in patients |                                                      |            |
|                                               |     | \( MTHFR \) C677T 0.299 in controls and 0.357 in patients |                                                      |            |
| 60 women who experienced RPL and 80 female controls | 140 | FVL 0.0188 in controls and 0.075 in patients | significant difference in allele distribution between the study groups for FVL and \( MTHFR \) C677T | (29)       |
|                                               |     | FII G20210A 0.0063 in controls and 0.025 in patients |                                                      |            |
|                                               |     | \( MTHFR \) C677T 0.25 in controls and 0.3917 in patients |                                                      |            |
|                                               |     | \( PAI-1 \) 4G/5G 0.2 in controls and 0.3 in patients |                                                      |            |

*B&H – Bosnia and Herzegovina, DVT – deep vein thrombosis, FII – factor II, FVL – factor V Leiden, FXIIIA1 – factor XII variant A1, MAF – minor allele frequency, \( MTHFR \) – methylenetetrahydrofolate reductase, \( PAI-1 \) – plasminogen activator inhibitor 1, PL – pregnancy loss, RPL – recurrent pregnancy loss.
Marker PAI-1 c.-844G>A had even higher prevalence in our population, with -844A allele having the frequency of 0.588, which is very close to the European average of 0.594 (Table 6).

Variant F13A1 c.103G>T, also known as Val35Leu, has been assigned a protective role against venous thromboembolism, myocardial infarction (48,34), and coronary artery disease (35). MAF of 0.315 for this marker obtained in the present study is somewhat higher than previously reported T allele prevalence of 0.242 in Caucasians (Table 6).

Mutations in the latter three genes are considered to have additive value to other risk factors, including FVL and PTM mutations. Also, PAI-1 variants were found to have a strong additive role in the increased incidence of myocardial infarction in the presence of metabolic syndrome risk factors, such as increased cholesterol and triglyceride levels (36).

Variant c.-1639G>A in the VKORC1 gene is one of the most extensively studied markers of warfarin pharmacodynamics. Its mutant allele A is associated with 2-fold lower gene expression and consequential lower warfarin requirements, increased risk of bleeding events, and international normalized ratio (INR)>4. The same is true for haplotypes A (warfarin-sensitive) and B (warfarin-resistant), consisting of c.-1639G>A and four additional loci, including c.174-136C>T and c.283 + 124G>C, inherited together due to extremely high level of linkage disequilibrium (37,38), which was proven in the current study as well.

When it comes to worldwide allele frequencies of c.-1639G>A, variant allele A is the most frequent in East Asians (0.86), followed by Europeans (0.37) and Africans (0.10). In US Hispanic population, MAF for this marker was 0.46 (39). The results from the current study for VKORC1 variants are in alignment with previously published literature, especially two previous studies of VKORC1 polymorphisms c.1173C>T and c.1639G>A in Croatia. In the study by Mandić et al on 420 unrelated healthy individuals from Eastern Croatia, these two loci were in perfect linkage disequilibrium, with major and minor allele frequencies of 0.593 and 0.407, respectively (40). Another study analyzed the same two variants in 186 Croatian patients on stable warfarin therapy and found wild-type, heterozygous, and mutant homozygous genotypes frequencies to be 33.9%, 46.8%, and 19.4%, respectively (41).

VKORC1 variants c.-1320G>A and c.-679A>G, together with missense change Asp36Tyr from exon 1 of the same gene, make up a haplotype that predisposes to high warfarin requirements, and these variants are more common in Jewish individuals than in other ethnic groups (42,43). However, these two loci were not polymorphic in general Bosnian-Herzegovinian population.

CYP2C9*2 allele (CYP2C9 c.430C>T) was the first CYP2C9 variant discovered and it stays the most studied SNP on this gene. Arg144Cys substitution encoded by this SNP disables a proper interaction of cytochrome P450 with NADPH-dependent cytochrome P450 oxidoreductase and decreases the rate of enzyme activity. Another important variant, CYP2C9 c.1075A>C (CYP2C9*3), influences enzyme conformation, thus lowering its ability to bind different substrates, including warfarin (44). Daly et al report the global frequency of allele *2 of 0.0914, while allele *3 is less common, with an average worldwide frequency of 0.0637 (45). A previous population genetic study of CYP2C9 polymorphisms in 200 unrelated individuals in Croatian population yielded results similar to ours. Alleles *2 and *3 had frequencies of 0.165 and 0.095, respectively (46). In the study of 129 healthy Slovenian individuals, alleles *2 and *3 had frequencies of 0.122 and 0.063, respectively (47). The only previous study on CYP2C9*2 allele in Bosnian-Herzegovinian population is published by Veljić et al (48) with MAF of 0.12, and it is in alignment with our findings.

TABLE 6. The summary of the 1000 Genomes Project phase III findings (31). Minor allele frequency of six alleles in five global populations is given, namely African, admixed American, East Asian, European, and South Asian. Data for PAI-1 4G/5G were not available. Complete data set was retrieved from PharmGKB database (32)*

|                | African (n = 1322) | Admixed American (n = 694) | East Asian (n = 1008) | European (n = 1006) | South Asian (n = 978) |
|----------------|-------------------|---------------------------|-----------------------|---------------------|-----------------------|
| FVL not detected | 0.012             | 0.010                     | not detected          | 0.011               |
| FII G20210A not detected | 0.014             | 0.010                     | not detected          | 0.008               |
| MTHFR C677T 0.090 | 0.474             | 0.296                     | 0.365                 | 0.119               |
| MTHFR c. 1286A>C 0.151 | 0.151             | 0.219                     | 0.313                 | 0.417               |
| PAI-1 c.-844G>A 0.247 | 0.372             | 0.393                     | 0.594                 | 0.492               |
| FXIII A1 V35L 0.164 | 0.269             | 0.002                     | 0.242                 | 0.093               |

*FII – Factor II, FVL – Factor V Leiden, FXIII A1 – Factor XIII variant A1, MTHFR – methylenetetrahydrofolate reductase, PAI-1 – plasminogen activator inhibitor 1.
ian population, which investigated the impact of this allele on the susceptibility to type 2 diabetes mellitus (T2DM) by genotyping 37 T2DM patients and 44 healthy controls, reported a low mutant allele frequency of 0.09 (48).

Novel or direct oral anticoagulants (NOACs, DOACs) are presently considered as an important improvement to traditional oral anticoagulation therapy, since they are less prone to interpatient variation, have stable pharmacokinetic and pharmacodynamic profiles exhibiting less interactions, and do not require frequent INR monitoring, thus decreasing or abandoning the need for warfarin dosing algorithms (13,49). European Society of Cardiology generally gives advantage to NOACs over VKA therapy for stroke prevention in AF (50) and treatment of deep vein thrombosis (51). While relevant data on NOAC usage in B&H are currently not available, the BALKAN-AF survey conducted in seven countries, including B&H, reported 10.1% of all patients on oral anticoagulation therapy to be taking NOACs prior to study enrollment. This number increased to 17.2% following the enrolling visit or hospitalization (52).

The limitations of the present study include the limited non-representative sample size of 130 individuals from the general population. This study thus does not offer information on the risk of thromboembolic events or recommendations for warfarin dosing at the population level. It is also important to note that this study alone does not provide guidelines regarding the duration or intensity of warfarin therapy in Bosnian-Herzegovinian patients. Future research should study the prevalence of the major genetic variants, including FVL, F2 c.*97G>A (PTM), VKORC1 c.-1639G>A, and CYP2C9 variants c.430C>T and c.1075A>C in a study group of warfarin-anticoagulated patients and a control group to assess their importance for personalization of antithrombotic treatment.

This is the first study reporting general population data for a panel of 14 genetic variants of inherited thrombophilia and warfarin pharmacogenetics in B&H. The results show that these genetic variants are considerably present in the general population of B&H. The frequency of detected minor variants is in agreement with previously published data for European populations. Implications of this study are important in that it paves the way for an integrated analysis of patient’s unique genomic makeup to offer individualized prophylaxis and treatment of thrombotic events.

References
1. Palta S, Saroja R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58:15-23. Medline:25535411 doi:10.4103/0019-5094.144663
2. Stevens SM, Woller SC, Bauer RA, Kathuri R, Cushman M, Streiff M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41:154-64. Medline:26780744 doi:10.1007/s11239-015-1316-1
3. Kujovich JL, Factor V. Leiden thrombophilia. Genet Med. 2011;13:1-16. Medline:21116184 doi:10.1097/GIM.0b013e3181f80f0f
4. Sykes TCF, Fegan C, Mosquera D. Thrombophilia, polymorphisms, and vascular disease. Mol Pathol. 2000;53:300-6. Medline:11193048 doi:10.1136/myp.53.6.300
5. Kujovich JL. Prothrombin-related thrombophilia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. Gene Reviews. Seattle, WA, USA: University of Washington, Seattle, 2014.
6. Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008;38:15-23. Medline:18282807 doi:10.1016/j.transci.2007.12.005
7. Eterović D, Titlić M, Ćulić V, Zadro R, Primorac D. Lower contribution of factor V Leiden or G20210A mutations to ischemic stroke in patients with clinical risk factors: pair-matched case-control study. Clin Appl Thromb Hemost. 2007;13:188-93. Medline:17456629 doi:10.1177/1076029606298999
8. Cushman M, Cornell A, Folsom AR, Wang L, Tsai MY, Polak J, et al. Associations of the β-fibrinogen Haelli and factor XII Val34Leu gene variants with venous thrombosis. Thromb Res. 2007;121:339-45. Medline:17582472 doi:10.1016/j.thromres.2007.05.009
9. Hickey SE, Curry CJ, Torelli HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15:153-6. Medline:23288205 doi:10.1038/gim.2012.165
10. Cavallari LH, Shis J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. 2011;31:1192-207. Medline:22122181 doi:10.1592/phco.31.12.1192
11. Höppner W, Primorac D. Pharmacogenetics in clinical practice:
experience with 16 commonly used drugs. Zagreb: St. Catherine Specialty Hospital; 2016.

12 Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397-404. Medline:28198005 doi:10.1002/cpt.668

13 O’Connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: a pharmacogenetic review of newer antiplatelets (clodipogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13:725-39. Medline:28571507 doi:10.1080/17425255.2017.1338274

14 Shaikh SI, Kumari RV, Hegade G, Marutheesh M. O’Connor CT, Kiernan TJ, Yan bP. The genetic basis of antiplatelet and anticoagulant therapy: a pharmacogenetic review of newer antiplatelets (clodipogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13:725-39. Medline:28571507 doi:10.1080/17425255.2017.1338274

15 Kovačević L, Fatur-Cerić V, Hadžić N, Čakar J, Primorac D, bajrović K, 16 Marjanović D, Pojskić N, Bakal N, Drobnič K, Primorac D, 15 Kovačević L, Fatur-Cerić V, Hadžić N, Čakar J, Primorac D, 14 Shaikh SI, Kumari RV, Hegade G, Marutheesh M. O’Connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: a pharmacogenetic review of newer antiplatelets (clodipogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13:725-39. Medline:28571507 doi:10.1080/17425255.2017.1338274

16 Marjanović D, Pojskić N, Bakal N, Drobnič K, Primorac D, Bajrović K, et al. Preliminary population study at fifteen autosomal and twelve Y-chromosome short tandem repeat loci in the representative sample of multinational bosnia and Herzegovina residents. Int Congr Ser. 2006;1288:243-5. doi:10.1016/j.csc.2005.09.138

17 Miller SA, Dykes DD, Polesky HFRN. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215. Medline:3344216 doi:10.1093/nar/16.3.1215

18 Storm N, Darnhofer-Patel b. MALDI-TOF mass spectrometry-based SNP genotyping. In: Kwok P-J, editor. Single nucleotide polymorphisms. Totowa, NJ, USA: Springer; 2003. p. 241-62.

19 Peakall R, Smouse PE. GenAlEx 6: genetic analysis in Excel. Population genetic software for teaching and research. Mol Ecol Notes. 2006;6:228-30. doi:10.1111/j.1471-2286.2005.01155.x

20 Peakall R, Smouse PE. GenAlEx 6.5: genetic analysis in Excel. Population genetic software for teaching and research - an update. Bioinformatics. 2012;28:2537-9. Medline:22820204 doi:10.1093/bioinformatics/bts460

21 Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Hered. 1995;86:248-9. doi:10.1093/oxfordjournals.jhered.a111573

22 Rousset F. GenePop007: a complete reimplementation of the GenePop software for Windows and Linux. Mol Ecol Resour. 2008;8:103-6. Medline:21585727 doi:10.1111/j.1471-8286.2007.01931.x

23 Dean L. Warfarin therapy and the genotypes CYP2C9 and VKORC1. In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Medical genetics summaries. Bethesda, MD: National Center for Biotechnology Information; 2016.

24 Valjevac A, Mehić B, Kiseljaković E, Ibrulj S, Garstka A, Adler G. Prevalence of 1691G>A FV mutation in females from Bosnia and Herzegovina – a preliminary report. Bosnian J Basic Med Sci. 2013;13:31-3. Medline:23448608 doi:10.17305/bjms.2013.2410

25 Karić A, Terzić R, Jerkić Z, Mustedana-Džudanović J. The frequency of C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism in Southern East Bosnian population. J Biom Biostat. 2013;4:169-71.

26 Adler G, Agnieszka G, Valjevac A, Czerska E, Kiseljaković E, Salkić NN. Prevalence of genetic prothrombotic risk factors: 1691G>A FV, 20210G>A PT and 677C>T MTHFR mutations in the Bosnian population. Ann Hum Biol. 2015;42:576-80. Medline:25357225 doi:10.3109/03014460.2014.968618

27 Jusić-Karić A, Terzić R, Jerkić Z, Avdić A, Podanin M. Frequency and association of 1691 (G>A) FVL, 20210 (G>A) PT and 677 (C>T) MTHFR with deep vein thrombosis in the population of Bosnia and Herzegovina. Balkan J Med Genet. 2016;19:43-50. Medline:27785407 doi:10.1515/bjmg-2016-0006

28 Mahmutbegović E, Marjanović D, Mededović E, Mahmutbegović N, Dogan S, Valjevac A, et al. Prevalence of F5 1691G>A, F2 20210G>A, and MTHFR 677C>T polymorphisms in Bosnian women with pregnancy loss. Bosnian J Basic Med Sci. 2017;17:309-14. Medline:28488549

29 Jusić A, Barać B, Avdić A, Podanin M, Balic A. The association of factor V G1691A (factor V Leiden), prothrombin G20210A, MTHFR C677T and PAI-1 4G/5G polymorphisms with recurrent pregnancy loss in Bosnian women. Med Glas (Zenica). 2018;15:158-63. Medline:29703881

30 Adler G, Clark JS, Lonievska B, Czerska E, Salkić NN, Ciechanowicz A. Prevalence of 1691G>A FV mutation in Poland compared with that in other Central, Eastern and South-Eastern European countries. Bosnian J Basic Med Sci. 2012;12:82-7. Medline:22642591

31 The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68-74.

32 Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414-7. Medline:22992668 doi:10.1038/clpt.2012.96

33 Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methyleneetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28:621-47. Medline:23900608 doi:10.1007/s10654-013-9825-8

34 Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164:101-9. Medline:16740590 doi:10.1093/aje/wkl007
35 Byrnes JR, Wolberg AS. Newly-recognized roles of factor XIII in thrombosis. Semin Thromb Hemost. 2016;42:445-54. Medline:27056150 doi:10.1055/s-0036-1571343

36 Nikolopoulos GK, Bagos PG, Tsangaris I, Tiara CG, Kopterides P, Vaiopoulos A, et al. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clin Chem Lab Med. 2014;52:937-50. Medline:24695040 doi:10.1515/cclm-2013-1124

37 Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet. 2006;51:249-53. Medline:16432637 doi:10.1007/s10038-005-0354-5

38 Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-93. Medline:15930419 doi:10.1056/NEJMoa0430493

39 Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol. 2012;8:563-76. Medline:22871196 doi:10.2217/fca.12.31

40 Mandić D, Mandić S, Samardžija M, Samardžija M, Vitamin K epoxide reductase complex 1 (VKORC1) gene polymorphisms in population of Eastern Croatia. Coll Antropol. 2013;37:1321-6. Medline:24611351

41 Mandić D, Božina N, Mandić S, Samardžija M, Milostić-Srb A, Rumora L. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. Int J Clin Pharmacol Ther. 2015;53:905-13. Medline:26445138 doi:10.5414/CP202424

42 Bodin L, Perdu J, Diry M, Horellou MH, Loriot MA. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost. 2008;6:1436-9. Medline:18532998 doi:10.1111/j.1538-7836.2008.03049.x

43 Loebstein R, Dvoskin I, Halkin H, Vecller M, Lubetsky A, Rechavi G, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109:2477-80. Medline:17110455 doi:10.1182/blood-2006-08-038984

44 Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 CYP2C9 gene and its clinical significance. Curr Drug Metab. 2009;10:781-834. Medline:19925388 doi:10.2174/138920009789895480

45 Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. J Pers Med. 2017;8:1. Medline:29283396 doi:10.3390/jpm8010001

46 Božina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19 and CYP2D6 in Croatian population. Croat Med J. 2003;44:442-8. Medline:12950145

47 Herman D, Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39:4208-18. Medline:28329262 doi:10.1093/eurheartj/ehx210

48 Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. Medline:27567408 doi:10.1093/eurheartj/ehw210